Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 31,392 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose 2 Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy

NCT00388297
View directory record Official record
Conditions
Subclinical Hypothyroidism, Hypothyroxinemia, Pregnancy
Interventions
Levothyroxine, Placebo for Levothyroxine
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
1,203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 4 Interventional Results available

Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo

NCT02062710
View directory record Official record
Conditions
Cough Reflex Sensitivity
Interventions
diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo, diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo, dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa, placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan, placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

NCT01189760
View directory record Official record
Conditions
Facial Rhytides, Crow's Feet Lines, Glabellar Lines
Interventions
onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies

NCT00822523
View directory record Official record
Conditions
Muscle Strength, Botulinum Toxins, Type A
Interventions
Botulinum Toxin, Type A, Saline
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 54 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 29, 2026, 6:29 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

NCT00800280
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
PD 0332334, cimetidine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 17, 2010 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants

NCT06180980
View directory record Official record
Conditions
Healthy
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 29, 2026, 6:29 PM EDT
Recruiting Phase 4 Interventional

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

NCT06577779
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Methylphenidate Hydrochloride Extended Release Capsule
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 29, 2026, 6:29 PM EDT
Recruiting Phase 2 Interventional

A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

NCT06809179
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Fasedienol Nasal Spray - Placebo Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray, Placebo Nasal Spray - Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Sherman Oaks, California • Walnut Creek, California • Largo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers

NCT01672996
View directory record Official record
Conditions
Healthy
Interventions
Ioforminol 160 mgI/mL, Ioforminol 200 mgI/mL, Iopamidol 300 mgI/mL
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

NCT02303262
View directory record Official record
Conditions
Metastatic Leiomyosarcoma
Interventions
Mocetinostat, Gemcitabine
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)

NCT06733688
View directory record Official record
Conditions
Healthy
Interventions
Tedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

NCT00894803
View directory record Official record
Conditions
Ischemic Stroke, Stroke, Brain Infarction
Interventions
Eptifibatide, rt-PA
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

PDC-1421 Treatment in Adult Patients With ADHD

NCT05202327
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
PDC-1421 Capsule, Placebo
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 4 Interventional Results available

Dosing Flexibility Study in Patients With Rheumatoid Arthritis

NCT00580840
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
50
States / cities
Huntsville, Alabama • Montgomery, Alabama • Gilbert, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

NCT00050440
View directory record Official record
Conditions
Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT05496374
View directory record Official record
Conditions
Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Interventions
Placebo, SPR720 500 mg, SPR720 1000 mg
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
28
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

NCT02471274
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
4
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 29, 2026, 6:29 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

NCT05233618
View directory record Official record
Conditions
Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions
Tagraxofusp
Drug
Lead sponsor
Karen Ballen, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 29, 2026, 6:29 PM EDT
Withdrawn Phase 1 Interventional

Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)

NCT02276820
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Viralym-A
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

NCT00976820
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 8 Years
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
17
States / cities
Conway, Arkansas • Little Rock, Arkansas • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

NCT00715624
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin, Pen auto-injector
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 29, 2026, 6:29 PM EDT
Terminated Not applicable Interventional Results available

A Phase I/II Dose Escalation Study Using Extracranial Stereotactic Radiosurgery to Control Pain

NCT00802659
View directory record Official record
Conditions
Metastases
Interventions
Stereotactic radiotherapy
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

NCT02735980
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Prexasertib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
14
States / cities
Fayetteville, Arkansas • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 29, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects

NCT02256488
View directory record Official record
Conditions
Prophylaxis: Influenza
Interventions
TIVc_LOT A, TIVc_LOT B, TIVc_LOT C, TIVf
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,561 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
24
States / cities
Anaheim, California • Redding, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 29, 2026, 6:29 PM EDT